Administration of AZD6738 — Competitive Intelligence Brief

Administration of AZD6738 (Administration of AZD6738) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ATR kinase inhibitor. Area: Oncology.

phase 1 ATR kinase inhibitor ATR Oncology Small molecule

Target snapshot

Administration of AZD6738 (Administration of AZD6738) — AstraZeneca. AZD6738 is a selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase, which plays a critical role in the DNA damage response pathway.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Administration of AZD6738 TARGET	Administration of AZD6738	AstraZeneca	phase 1	ATR kinase inhibitor	ATR
Praxbind	IDARUCIZUMAB	Boehringer Ingelheim	marketed	Humanized Monoclonal Antibody Fragment [EPC]	dabigatran and its acylglucuronide metabolites	2015-01-01
Natrecor	NESIRITIDE	Scios Llc	marketed	Natriuretic Peptide	Atrial natriuretic peptide receptor 1	2001-01-01
Monoket	ISOSORBIDE MONONITRATE		marketed	Nitrate Vasodilator [EPC]	Atrial natriuretic peptide receptor 1	1991-01-01
CEFOTIAM	CEFOTIAM		marketed	cefotiam	Vasoactive intestinal polypeptide receptor 1, Matrix metalloproteinase-9, Bacterial penicillin-binding protein	1988-01-01
Monocid	CEFONICID		marketed	cefonicid	Matrix metalloproteinase-9	1984-01-01
Dtic-Dome	dacarbazine	Bayer	marketed	Alkylating Drug [EPC]	Matrix metalloproteinase-9	1975-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ATR kinase inhibitor class)

1. AstraZeneca · 2 drugs in this class